Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Next Previous
X
Search
Trial Profile

Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Diffusion Pharmaceuticals

    • Most Recent Events

    • 15 Nov 2018 According to a Diffusion Pharmaceuticals media release, results from this study will be presented at the 2018 Annual Meeting of the Society for NeuroOncology (SNO) (Nov 2018).
    • 01 Jun 2018 NCT mention trial as phase 1/2 trial,whereas MR-9241881 mention is as phase 2 study kept phase as per NCT
    • 08 Feb 2017 According to Diffusion Pharmaceuticals media release, data from this study has been published in the print edition of the peer-reviewed Journal of Neurosurgery.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top